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The effect of conversion from cyclosporine-steroid im-
munosuppression to the new agent FK506 was studied 
in 96 liver allograft recipients who were experiencing 
graft dysfunction or cyclosporine toxicity. Patients 
were stratified according to the cause of graft dysfunc-
tion that ultimately led to conversion to FK506. Re-
sponse to FK506 introduction was monitored patholog-
ically and biochemically. The outcome of a switch from 
CsA to FK506 was highly favorable in patients experi-
encing acute and the early stages of chronic rejection, 
despite optimal conventional therapy. Patients with 
later stages of chronic rejection did not respond to con-
version to FK506 and most eventually lost their liver 
grafts in this process. Patients in whom we had diffi-
culty separating chronic rejection from chronic persist-
ent or low-grade chronic active hepatitis were mostly 
unaffected by conversion to FK506. Active hepatitis was 
a poor indication for conversion, because most of the 
patients experienced graft failure or died from liver 
failure. As a group, there was no statistically significant 
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change in renal function 180 days after conversion to 
FK506. These findings expand the experience with 
FK506 in human liver allograft recipients. 
The new immunosuppressant FK506 was first used in hu-
mans for the treatment of acute and even relatively advanced 
chronic liver graft rejection (1-3). This report is of a much 
longer experience and with longer follow-up. An attempt was 
made to correlate the histopathologic findings and biochemical 
parameters before and after FK506 was given as a "rescue" 
agent. FK506 was offered to patients whose grafts became 
dysfunctional despite standard esA/steroid immunosuppres-
sion. 
MATERIALS AND METHODS 
Patient selection. The clinicopathologic profile was reviewed of all 
liver allograft recipients who were switched from CsA/steroid to FK506 
therapy during the period of 03/01/89 (first day of use in humans) until 
12/15/89. During this time, 136 patients were converted. Ninety-six 
who met the following criteria were selected for more detailed study on 
the basis of the following: (1) biochemical graft dysfunction, as defined 
by elevated liver function tests (>50% over normal values) without 
evidence of mechanical causes (e.g., biliary obstruction or vascular 
occlusion; (2) availability of a liver biopsy within 7 days before the 
switch, with at least one follow-up biopsy. The other 38 cases were 
excluded because a preswitch biopsy was not obtained (n=22), because 
no follow-up biopsy was available (n=10), because the drug switch was 
at the time of transplantation (n=7), or because diagnosis causing the 
decision for the drug change was erroneous (n=I). 
The age, sex, duration of CsA therapy, previous liver transplant(s) 
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and cause of previous graft failure(s) in the 96 patients studied are 
shown in Table 1. The case mix was similar to that in our group from 
throughout the years (4). Eighteen of the 96 patients qualified for 
inclusion on grounds of minor hepatic dysfunction, but had other and 
more important justifications for a drug change such as steroid or 
cyclosporine toxicity. These patients had generally less-advanced his-
topathologic alterations in the liver grafts than the others. This 
subgroup of 18 patients will not be discussed further because neither 
the minimally perturbed hepatic function tests nor the histopathologic 
findings was significantly altered by the change in therapy. 
The final decision to convert from CsA to FK506 was ultimately 
made by the clinicians. The liver function tests, the clinical reason for 
conversion and clinicopathologic profile of the patient prior to the 
switch were recorded (Table 2). The patients were followed until 9/1/ 
90, graft failure, or death, whichever came first. The details of therapy 
during the drug switch and after have been reported elsewhere (1,2, 
TABLE 1. Profile of patients who were switched from CsA to FK506 
A. 
Total number of patients 
Male/female 
Average age (yrs. [range]) 
Average days on CSA prior to the switch 
(range) 
B. 
Graft number at the time of conversion 
First 
Second 
Third 
Fourth 
C. 
Causes of prior graft failure(s) under CsA a 
Acute cellular rejection 
Chronic rejection 
Primary dysfunction/preservation injury 
Bile duct complication 
Hepatic artery thrombosis 
Total 
96 
57/39 
42 (1-74) 
640 (4-2402) 
No. patients 
75 
14 
5 
2 
No. grafts 
2 
14 
11 
1 
2 
30 
a Causes of prior graft failures under CsA, in patients who were 
switched to FK506 with a nonprimary graft in place. For example, if a 
patient had lost a prior graft to chronic rejection under CsA, and was 
recapitulating the course in a second graft, requiring conversion to 
FK506, the cause of failure in the first graft is listed as chronic rejection. 
TABLE 2. Clinicopathologic profile of patients at the time of 
conversion from CsA to FK506a 
Clinical reason for conver- No. Biopsy diagnosis No. Days ofCsA 
sion pts. pts. therapy (range) 
Rejection 76 Acute or chronic 18 173 (10-1401) 
CR/hep.b 33 624 (10-2402) 
20 905 (170-2089) 
CsA/steroid side effects 14 OtherC 18 270 (4-1797) 
or other reason 
Predominantly hepatitis 6 Hepatitis 7 672 (91-1743) 
Totals 96 96 640 (4-2402) 
a Pre-FK506 laboratory values (mean [range]): total bilirubin (mg/ 
dt) 7.1 (0.3-39.4); AST (IU/L) 195 (13-1040); ALT (lUlL) 300 (9-
1229); AP (IU/L) 381 (56-1730); gGTP (lUlL) 951 (51-5830); BVN 
(mg/dl) 37 (8-115); creatinine (mg/dl) 1.8 (0.3-5.5). 
b CR/hep = overlap between chronic rejection and chronic persistent 
or low-grade chronic active hepatitis. 
C Other includes clinically suspected rejection, not verified patholog-
ically, preservation injury, and mild portal inflammation. 
5). In essence, cyclosporine was stopped at the time FK506 was started, 
and prior steroid doses were reduced or discontinued. Azathioprine was 
also discontinued. The factor of hepatic dysfunction in reducing the 
beginning and maintenance doses of FK506 from the standard of 0.3 
mg/kg/day has been emphasized in recent studies.' Failure to make 
those reductions based on nephrotoxicity, neurotoxicity, and plasma 
monitoring of FK506 levels is a source of potential tragedy since the 
ability to metabolize this drug is inversely related to the quality of liver 
function" For those patients who survived with the same graft until 9/ 
1/90, liver function studies were recorded at 30, 60, 90, and 180 days 
after conversion (5). The normal range for liver and kidney function 
tests is as follows: total bilirubin(TB)* <1.5 mg/dl; alanine aminotrans-
ferase <40 IV/ml; aspartate aminotransferase <40 IV/ml; alkaline 
phosphatase <130 IV/ml; gamma glutamyl transpeptidase(gGTP) 
<120 IU/ml; and creatinine <1.5 mg/dl. 
Pathologic studies. All posttransplant pathology specimens taken 
from these patients were reviewed by a single pathologist (A.J.D.). 
Standard histopathologic criteria for the diagnosis of acute cellular 
rejection - and nonrejection -related syndromes were employed (4) on 
H&E-stained, 6-1L sections. Biopsies were considered adequate if 4 or 
more portal triads were identified. 
An attempt was made to temporally categorize the changes associ-
ated with "chronic" rejection, based on our previous experience (4). A 
diagnosis of "early" chronic rejection was made when there was evi-
dence of lymphocytic bile duct damage in 50% or more of the triads, 
bile duct loss limited to less than 25% of the triads, and no cholestasis 
or other lobular changes. A pathologic diagnosis of "late" chronic 
rejection was defined by duct loss in more than 50% of the triads, 
lymphocytic duct damage in the remaining bile ducts, and hepatocan-
alicular cholestasis and other lobular changes associated with "chronic" 
rejection (4). 
The biopsies were rereviewed without knowledge of the original 
disease, clinical course, or liver biochemical profile for assessment of 
the effect of FK506. However, the pathologist was aware of the temporal 
sequence of the biopsies and the date of FK506 introduction. The effect 
of FK506 on hepatic morphology was graded as "improved," "wors-
ened," or "no change" based on an overall assessment of the severity 
of portal and/or lobular inflammation, bile duct damage, hepatocyte 
necrosis, and architectural distortion. 
RESVLTS 
Entry diagnosis as a function of the original disease. The entry 
or Pre-FK506 diagnosis, as a function of the original disease is 
shown in Table 3. A biopsy diagnosis of either hepatitis or 
overlapping chronic rejection and chronic hepatitis was more 
prevalent in patients with hepatitis B-induced, autoimmune, 
NANB-induced, or cryptogenic cirrhosis prior to transplanta-
tion. Rejection was a more common reason for conversion in 
the other patients. 
Patient and graft status after conversion. The patient and 
graft status as of 09/01/90 as a function of the entry diagnosis 
is shown in Table 4. The original disease had no statistically 
significant effect on patient or graft survival after conversion 
(data not shown). However, the rate of subsequent graft failure 
was slightly higher in patients with cryptogenic or non-A-, non-
B-induced cirrhosis as their original disease. In patients with 
functioning grafts, the average interval between the immediate 
pre-FK506 biopsy and the latest post-FK506 follow-up biopsy 
was 123 days. However, the average clinical follow-up was 314 
days. Graft failure under FK506 occurred at an average of 82 
days after conversion (range 11-279 days) and was most com-
mon in patients with an entry diagnosis of "late" chronic 
• Abbreviations: gGTP, gamma glutamyl transpeptidase; TB, total 
bilirubin. 
------_ .. _.--..... --------
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TABLE 3. Entry diagnosis (reason for switch) as a function of the 
original liver disease 
Original disease Entry diagnosis (No. [%]) 
No. (% of total) ACR" CR CR/hep. Hep. Other 
CC/NANB: 26 (27%) 2 (8) 12 (46) 7 (27) 4 (15) 1 
CAH-B: 9 (9%) 0(0) 2 (22) 4 (44) 0(0) 3 
PSC: 14 (15%) 5 (36) 6 (43) 1 (7) 0(0) 2 
PBC: 8 (8%) 2 (25) 2 (25) 1 (13) o (0) 3 
Met/other: 12 (12%) 3 (25) 4 (33) 3 (25) 1 (8) 1 
Alcoholic: 17 (18%) 4 (24) 4 (24) 3 (18) 1 (6) 5 
Biliary atresia: 5 (5 %) 2 (40) 3 (60) 0(0) 0(0) 0 
Carcinoma: 2 (2%) 0 0 0 0 2 
Autoimmune CAH: 3 0 0 1 (33) 1 (33) 1 
(3%) 
Total 18 33 20 7 18 
"CC/NANB = cyptogenic cirrhosis/non-A, non-B hepatitis; CAH-
B-hepatitis B virus-induced cirrhosis; PSC = sclerosing cholangitis; 
PBC = primary biliary cirrhosis; Met/other = metabolic and other; 
ACR = acute cellular rejection; CR = chronic rejection; CR/hep. = 
overlapping chronic rejection and chronic hepatitis; Hep. = chronic 
hepatitis. 
TABLE 4. Patient and graft status as of 9/01/90 as a function of the 
pre-FK506 diagnosis (top) 
Entry diagnosis Functioning Failed Died Total 
Acute rejection 14 1 3 18 
Chronic rejection 22 11 0 33 
CR/hep. 16 4 0 20 
Hepatitis 2 1 4 7 
Other 13 1 4 18 
Total 67 18 11 96 
rejection. A more detailed description of graft failures and 
deaths is given later. 
Effect of conversion to FK506. It should be noted that many 
of the post-FK506 liver biopsies did not coincide with dates on 
which tests used for assessing liver injury occurred. This fact 
probably accounts for some of the discrepancies noted between 
the pathologic and biochemical response to conversion. A flow 
diagram showing the outcome and pathologic response after 
conversion from CsA to FK506 is shown in Figure 1. A more 
detailed discussion of each clinicopathologic indication for con-
version is given below. 
Acute cellular rejection. Eighteen of the patients were 
switched because of acute cellular rejection, which varied his-
tologically from mild to severe. All but two of the 18 patients 
had received additional steroid therapy (n=12) and/or OKT3 
(n=7), prior to conversion. The two exceptions were converted 
primarily because of renal dysfunction but had coexistent re-
jection. Although the average time on CsA prior to the switch 
was 219 days, 12 of the 18 patients were switched in the first 
five weeks after transplantation. Two of these patients died 
within two weeks after conversion because of sepsis. Another 
died of recurrent hepatoma, and a fourth patient required a 
second liver because the primary graft failed from chronic 
rejection. Ten of the 14 remaining functional grafts showed 
histologic as well as biochemical normalization (Table 5). 
No change in the histologic findings were observed in the 
remaining four, although some biochemical improvement was 
seen (Table 5). In the 4 patients with functioning grafts but no 
change on biopsy, two had a pathologic follow-up of less than 
~fmprovement (n=lO) 
;1crnctionlKng~ 
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Failed (n=4) 
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FIGURE l. Histologic evaluation of biopsies from patients after con-
version to FK506. Eighteen patients were switched for reasons other 
than significant graft dysfunction. There were minimal pathologic 
alterations before and after conversion to FK506. They are not included 
here. 
TABLE 5. Comparison of laboratory values in patients with acute 
cellular rejection before and 180 days after conversion to FK506 
esA (days) 
FK506 (days) 
TB (mg/dl) 
AST (IU/L) 
ALT (IU/L) 
ALP (IU/L) 
gGTP (lUlL) 
BUN (mg/dl) 
CR (mg/dl) 
Pre·FK506" 
(mean [range]) 
219 (12-1401) 
343 (266-547) 
8.3 (0.6-30.3) 
96 (24-210) 
219 (34-1229) 
215 (56-429) 
284 (71-750) 
38 (5-101) 
2.0 (0.1-5.0) 
Values at 180 days" 
(mean [range]) 
0.5b (0.1-l.2) 
65' (21-141) 
82' (13-152) 
164' (74-448) 
123' (22-440) 
36' (14-84) 
1.9' (0.4-3.5) 
a Patient with functioning grafts as of 9/01/90 (n=14). 
b P<0.05 (paired t test) compared with pre-FK506 values. 
, ]»0.05 (paired t test) compared with pre-FK506 values. 
two weeks. Mild central venulitis developed in the third patient, 
70 days after beginning FK506, although the portal infiltrate 
had diminished. In the fourth, mild portal inflammation with 
focal duct damage was still present 66 days after conversion. 
"Chronic" rejection. Twenty-two of the 33 (67%) patients 
switched for chronic rejection have functioning grafts as of 09/ 
01/90. None of the patients switched for this indication has 
died, but 11 required retransplantation. Liver injury parameters 
were significantly worse in patients with chronic rejection 
whose grafts failed compared with those whose grafts were 
successfully rescued (Table 6). Thirteen of the 22 patients with 
intact grafts have shown histologic improvement, and 10 of 
these have also shown biochemical improvement. In the re-
maining 9, while no significant histologic difference was seen 
following conversion, 6 had a lowering of liver function abnor-
malities by 180 days. 
The histopathology present in liver biopsies from patients 
who ultimately were FK506 treatment failures manifested a 
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TABLE 6. Comparison of laboratory values in patients with chronic 
rejection as the indication for FK506 switch separated into those who 
failed and were rescued, as well as average liver biochemistries in 
patients at 180 days with currently functioning grafts 
CsA (days) 
FK506 (days) 
TB (mg/dl) 
AST (IU/L) 
ALT (IU/L) 
ALP (lUlL) 
gGTP (lUlL) 
BUN (mg/dl) 
CR (mg/dl) 
Pre·FK506 average values (range) Average values at 
--F-ai-le-d-g-ra-ft-s--F-un-c-ti-o-ni-n-g -gr-a-ft-s 180 days" 
572d (23-2158) 825 (27-2402) 
47 (11-180) 316 (268-426) 
21' (0.9-39.4) 4.3 (0.3-20) 
282d (48-803) 204 (26-618) 
412" (123-964) 297 (13-697) 
666d (399-1359) 478 (65-1702) 
1661d (244-4076) 1316 (138-5332) 
33 (9-85) 33 (8-75) 
1.3 (0.3-4.7) 1.8 (0.5-5.1) 
l.lb (0.2-7.0) 
97b (8-310) 
126b (4-536) 
326e (41-985) 
677b (35-3200) 
35e (10-117) 
1.8e (0.3-4.6) 
"In patients with functioning grafts (n=11 for failed grafts; n=22 
for functioning grafts). 
b P<0.05 (paired t test) compared with pre-FK values in functioning 
grafts. 
e P<0.05 (t test) compared with pre-FK506 values in patients with 
functioning grafts. 
d P>0.05 (t test) compared with pre-FK506 values in patients with 
functioning grafts. 
e P>0.05 (paired t test) compared with pre-FK506 values in func-
tioning grafts. 
later stage of chronic rejection as compared with those who 
have maintained viable grafts. 
All but four of the patients who failed a rescue attempt had 
pre-FK506 biopsies that were characterized by bile duct loss in 
50% or more of the triads (Fig. 2). Other stigmata of late 
chronic rejection, including mild portal inflammation, choles-
tasis, hepatocyte dropout in zone 3 of the acinus, and periven-
ular fibrosis were also seen in the grafts that failed to respond. 
Although no single histopathologic parameter was able to pre-
dict a nonresponse to therapy, the combination of a TB >20 
mg/dl combined with greater than 50% duct loss on biopsy was 
highly predictive of nonresponse. 
In three of the four patients with milder changes on entry, 
the ultimate cause of graft failure was not chronic rejection. 
One of the patients initially responded to FK506 but lost his 
graft because of arterial thrombosis at the suture line. Another 
patient normalized her liver function only to lose the graft, 6 
months after conversion, to a combination of hepatitis and 
rejection. Examination of the failed graft in this patient re-
vealed duct loss limited to 30% of the triads, centrilobular 
perivenular hepatocyte dropout, and fibrosis. Biliary sludge 
with ascending cholangitis was the ultimate cause of graft 
failure in the third patient. 
Entry liver biopsies from patients with functioning grafts 
180 days after conversion to FK506 showed less severe damage 
from chronic rejection. Ongoing lymphocytic bile duct damage 
was present in biopsies from all patients but duct loss was seen 
in 50% or less of the triads in all but two cases (Fig. 2). The 
coexistent lobular changes mentioned above were less frequent. 
Because of the possibility of sampling errors, it was not possible 
to state that bile duct regrowth occurred with rescue, but in 
several patients the percent of duct loss was less in follow-up 
biopsies. A comparison of the degree of duct loss between the 
successful rescues and the treatment failures is illustrated 
graphically in Figure 2. 
Most often histologic improvement was marked by a decrease 
merc_~K~t 
Duct Loss 
.... 
.... 
Functioning 
Grafts 
Failed 
Grafts 
FIGURE 2. Percent bile duct loss in biopsies taken prior to conver-
sion to FK506. 
in portal inflammation and accompanying bile duct damage. 
This was particularly true if there had been a moderate portal 
infiltrate before conversion to FK506. In other cases, portal 
inflammation remained stable but bile duct damage decreased. 
Paradoxically, in some cases the cholestasis present in biopsies 
increased shortly after the initiation of FK506, only to resolve 
later. 
Resolution of the biochemical abnormalities in patients with 
chronic rejection who have responded to FK506 occurred over 
a period of weeks to months. Dwindling serum bilirubin values 
and a loss of clinical jaundice were often the first signs of 
success. Dramatic declines were also observed in the canalicular 
enzymes (gGTP and ALP), although many of the patients still 
had elevations of these two enzymes 180 days after conversion 
(Table 6). Overall, there was a statistically significant (P<0.05) 
decrease in total bilirubin, AST, ALT, and gGTP. The levels 
of AP were also lower, but the difference did not reach statis-
tical significance. 
Overlapping chronic rejection and hepatitis. Sixteen of the 20 
(80%) patients switched because of an entry biopsy diagnosis 
of overlapping chronic rejection and chronic persistent or low-
grade chronic active hepatitis have retained their grafts. None 
of the patients in this group died. Four required retransplan-
tation-one because of chronic rejection, one from hepatitis, 
one from a combination of chronic rejection and hepatitis, and 
one because of severe atherosclerotic narrowing of an arterial 
graft as well as hepatitis. In general, the pathologic alterations 
and liver function abnormalities prior to FK506 in this group 
were persistent but were not severe (Table 7). 
Histologically, most patients (ten) in this group have stayed 
the same or showed less portal inflammation and duct damage 
after conversion to FK506. Despite the histologic assessment 
in this group, statistically significant (P<0.05) lowering of the 
total bilirubin, AST, and AL T values were observed 180 days 
after conversion. An overall worsening of the pathologic find-
ings was seen in 5 patients. In 4, the deterioration was a result 
of increased hepatitic activity, that assumed a "cholestatic" or 
chronic active pattern. The former was characterized by lobular 
disarray and steatosis, hepatocyte swelling and spotty necrosis, 
cholestasis, and a conspicuous paucity of inflammation. These 
changes were accompanied by cholangiolar proliferation; acute 
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TABLE 7. Comparison of laboratory values in patients with an entry 
diagnosis of chronic rejection/CPH, and low-grade CAH beforehand 
and at 180 days following FK506 conversion 
CsA (days) 
FK506 (days) 
TB (mg/dl) 
AST (IU/L) 
ALT (lUlL) 
ALP (IU/L) 
gGTP (IU/L) 
BUN (mg/dl) 
CR (mg/dl) 
Pre-FK506" values 
(mean [range]) 
731 (170-1555) 
299 (264-344) 
1.1 (0.3-2.1) 
173 (21-411) 
291 (45-805) 
142 (81-308) 
413 (68-1540) 
26 (11-55) 
1.6 (0.9-2.8) 
Values at 180 days" 
(mean [range]) 
0.6b (0.1-1.3) 
85b (23-210) 
110b (22-256) 
154c (105-293) 
309' (18-907) 
32' (12-92) 
2.1b (1.0-4.4) 
"In patients with functioning grafts as of 9/01/90 (n=16). 
b P<0.05 (paired t test) compared with pre-FK506 values. 
, P>0.05 (paired t test) compared with pre-FK506 values. 
cholangiolitis; and a mild mixed, but often neutrophilic, portal 
and periportal infiltrate. In the last patient, both hepatitis and 
rejection activity increased. 
Hepatitis. Of the seven patients with hepatitis prior to FK506 
conversion, four have died, one lost his graft, and only 2 have 
functional grafts after 180 days. One of the latter patients 
showed both biochemical and histologic deterioration, due to 
rejection rather than hepatitis. This same patient had also lost 
a prior graft to chronic rejection. 
The last patient deserves a special description. The etiology 
of his original disease was never ascertained, with features of 
both autoimmune chronic active hepatitis and posttransfu-
sional (HCV antibody-positive) cirrhosis. After transplantation 
he experienced a three-year course of chronic active hepatitis, 
which on biopsy always had a heavy plasmacytic infiltrate, 
typical of autoimmune chronic active hepatitis. Although his 
bilirubin was normal at the time of conversion, he had eleva-
tions of AST and ALT 6-11 times normal with near-normal 
ALP and gGTP. However, his liver biopsy demonstrated early 
cirrhosis. Six months after starting FK506, his liver function 
tests were normal. The last liver biopsy, which was obtained 
89 days after conversion, showed less inflammation but per-
sistent fibrosis. 
Analysis of grafts failing under FK506. In most instances, the 
entry diagnosis explained why the graft failed (Table 8). Only 
one patient, whose ultimate cause of graft failure was chronic 
rejection despite conversion to FK506, would not have been 
considered for retransplantation if FK506 had not been avail-
able. Only one patient with an entry diagnosis of acute cellular 
rejection did not respond to conversion, leading to a need for 
retransplantation. In this patient, the lesion had progressed to 
chronic rejection when the graft was finally removed. 
Nonetheless, there were several exceptions in which the 
diagnosis at entry was not the cause of graft failure (Table 8). 
In 2/11 cases a pre-FK biopsy diagnosis of chronic rejection 
was not confirmed on examination of the failed graft. These 
inconsistencies were most likely the result of an erroneous pre-
FK506 pathologic diagnosis. Biliary sludge was found in the 
deep hilar bile ducts in both grafts at retransplantation and 
was likely the major cause of failure. Portal fibrosis, focal small 
bile duct loss involving less than 25% of the triads, and choles-
tasis were seen in the subcapsular region, without obliterative 
arteriopathy. In a third case the cause of ultimate graft loss 
was uncertain. Severe sclerosis of the terminal hepatic venules 
TABLE 8. Cause of graft failure under FK506 as a function of the 
reason for conversion from CsA 
Cause of graft failure 
Entry diagnosis 
ACR CR CR/hep. Hep. Other Total 
Acute rejection 0 0 0 0 0 0 
Chronic rejection 1 7 2 0 0 10 
Hepatitis 0 0 1 0 2 
Biliary tract prob- 0 2" 0 0 0 2 
lem 
Hepatic artery 0 Ib 0 0 0 1 
thrombosis 
Other 0 1 ' 1d 0 1" 3 
Totals 1 11 4 1 1 18 
a Examination of the failed graft revealed biliary sludge in the deep 
hilar region and focal duct loss without arteriopathy. 
b The patient initially responded to FK506, but the graft failed 
because of thrombosis at the arterial suture line. 
'The cause of failure is uncertain. Severe sclerosis of terminal 
hepatic venules and early cirrhosis were found in the failed graft. 
d There was severe atherosclerosis of arterial graft and hepatitis. 
'There was a mistaken pathologic diagnosis; a portal vein-bile duct 
fistula was found in failed graft that was missed on pre-FK biopsy. 
and an early cirrhosis with prominent cholangiolar prolifera-
tion were the striking features. In a fourth graft, the early 
stages of chronic rejection were confirmed in the failed graft, 
but they appeared to have been lost because of an unrecognized 
arterial thrombus at the suture line. 
Questions of toxicity. Acute FK506 nephrotoxicity (a revers-
ible rise in serum creatinine) was obvious in the first patients 
treated and was observed in the majority of patients (1,5,6). 
This was most severe when intravenous FK506 was used in 
patients with severe hepatic dysfunction resulting in extremely 
high drug levels. As reported previously, creatinine regularly 
rises after switching from cyclosporine to FK506 and falls 
toward baseline values after weeks of therapy. This crossover 
nephrotoxicity was attenuated in patients starting FK506 orally 
and at doses less than the standard 0.15 mg/kg given twice per 
day, which was our initial practice. 
Renal function in 25 of the 96 patients was studied with 
sequential iothalomete clearance for glomerular filtration rate 
and hippuran clearance for effective renal plasma flow. Baseline 
studies obtained within one week of initiating therapy and at 
120 days, respectively, were: ERPF 250.3±114 to 209±159.8 
ml/min and GFR 51.1±14.8 to 48.5±27.4 ml/min. The filtration 
fraction (GFR/ERPF) did not consistently change after con-
version. Since ERPF and GFR fell proportionately (causing 
little change in filtration fraction) no clear inferences can be 
made as to whether FK506 causes its effects primarily by 
vasoconstriction as cyciosporine does. Long term follow-up of 
these studies are in progress. 
Serum creatinine preconversion was 1.8±O.9 mg/dl (Table 9) 
and at one year 1.9±0.9 mg/dl. Peak creatinine (2.5±1.4 mg/ 
dl) for the group occurred at week 4 and progressively fell 
thereafter. In most cases the fall in creatinine was preceded by 
a reduction in drug dosage. In the first patients treated, cyclo-
sporine was continued during the initial days of conversion. 
This resulted in a dramatic rise in creatinine but did not require 
dialysis in any case. This was certainly due to the combined 
nephrotoxicity of FK506 and cyclosporine. 
No renal biopsies were performed either prior to the conver-
sion or after, precluding morphologic analysis of the possible 
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TABLE 9. Serum creatinine values as a function of the duration of 
esA therapy, immediately before and 180 days after the switch to 
FK506 (only patients with functioning grafts) 
Number of CsA Pre-FK506 Creatinine" after 180 
patients (days) creatinine" days of FK506 ther-
apy 
15 <100 1.9±1.7 (0.1-5.5) 1.6b±0.5 (0.4-2.3) 
4 100-200 2.0±1.8 (0.5-4.7) 1.6b±1.0 (0.9-3.0) 
7 200-300 2.5±1.7 (0.7-5.1) 2.0b±1.2 (0.3-3.6) 
42 >300 1.7±0.6 (0.6-3.1) 2.0b±0.9 (0.4-4.6) 
Total 68 1.8±0.9 (0.1-5.5) 1.9b±0.9 (0.3-4.6) 
a Values are given in mg/dl. 
b P>0.05 (paired t test) compared with pre-FK506 values. 
effects of FK506 on the native kidney. Such an analysis would 
require both preconversion biopsies and follow-up biopsies 
since the magnitude of cyclosporine-induced interstitial fibrosis 
was likely to be substantial. 
Deaths under FK506. Eleven patients died while being 
treated with FK506 at an average of 95 days after starting 
FK506 therapy (range 7-272 days). Six of the eleven died from 
sepsis, three during treatment for acute cellular rejection. An-
other died from recurrent hepatoma. Three of the patients died 
because of liver failure from hepatitis. In two, hepatitis (type 
B and presumed non-A-non-B) was diagnosed by biopsy prior 
to the switch to FK506. One patient died unexpectedly after 
approximately one year. However, she had been switched back 
to cyclosporine from FK506 6 months prior to her death because 
of availability of the FK506 during the early phase of our trials. 
Vascular morphology. These studies were largely limited to 
examination of failed allografts and liver allograft biopsies. 
Two allografts contained vascular lesions that were not readily 
explainable on the basis of rejection-related vasculopathy. Fo-
cal arterial medial necrosis was seen in one graft that failed 
because of presumed non-A, non-B hepatitis. Focal arterial 
medial scarring (possibly healed necrosis) was seen in another 
liver that failed primarily because of severe narrowing of a free 
arterial graft supplying a liver that had hepatitis. 
Hepatic morphology. There were two morphologic patterns of 
hepatic injury that could possibly be associated with the treat-
ments used. The first is probably best described as a cholestatic 
hepatitis. It was characterized by hepatocellular swelling, he-
patocanalicular cholestasis, lobular disarray, spotty acidophilic 
necrosis, cholangiolar proliferation, acute cholangiolitis, and a 
mild mixed portal infiltrate. It was most common in patients 
with cryptogenic cirrhosis, or non-A-non-B CAH/cirrhosis as 
their original disease, although all were not hepatitis C virus 
antibody-positive (data not shown). Because of the prior his-
tory of hepatitis in these patients, it was assumed that graft 
malfunction was virus-related. Consequently, discontinuance 
of FK506 was not considered. 
The second pattern of liver injury was centrilobular hepato-
cellular dropout, congestion with hemorrhage and mononuclear 
inflammation-and, ultimately, sclerosis of the terminal he-
patic venules. This lesion was present in some of the biopsies 
from 18 patients after the switch to FK506. However, in 11 of 
them, the same change was present while the patient was on 
GsA, at which time it was considered a manifestation of rejec-
tion. This particular lesion worsened in some of the biopsies 
taken after conversion to FK506 in 7 of the patients. The 
relative contribution of a concomitant reduction in steroids to 
the evolution of any of these changes, if any, cannot be directly 
addressed in this patient population beyond noting that a 
nearly universal strategy was to reduce or stop steroids after 
the change from CsA to FK506. 
Malignancies. One patient developed a secondary neoplasm 
after conversion to FK506. An IgA lambda monoclonal and 
monomorphic lymphoproliferative disorder was discovered on 
gastric biopsy. The lesion resolved promptly after lowering the 
FK506 dosage. 
DISCUSSION 
The data generated from this study could not be used for a 
comparison of FK506 with continuation of conventional ther-
apy. The latter option had already failed, particularly in pa-
tients who had lost previous grafts from chronic rejection and 
who were recapitulating the same course. A randomized exper-
iment in any of the patients was considered inhumane. Never-
theless, the experience yielded valuable information. 
FK506 provided more potent immunosuppression than that 
previously in effect, even though steroids were reduced or 
stopped and azathioprine was always discontinued. It was most 
effective for the treatment of patients experiencing acute cell-
ular or the early stages of chronic rejection, under optimal 
standard CsA and adjuvant immunosuppression. FK506 was 
less effective in patients in whom we were unable to confidently 
separate chronic rejection from a chronic persistent or low-
grade chronic active hepatitis as the cause of graft dysfunction. 
These patients had a mixed response pathologically, but most 
were unaffected, although a biochemical response was seen in 
many. Those with hepatitis alone fared poorly after conversion 
to FK506. The mixed or poor results obtained with patients 
experiencing what appeared to be an overlap of chronic rejec-
tion and hepatitis, or hepatitis alone, suggests that this should 
not be a prime consideration for conversion. Furthermore, the 
observed biochemical response could conceivably be the result 
of a natural resolution of hepatitic disease activity. 
In all of the cohorts, biochemical improvement was not 
uncommon even though this was not mirrored in the histopa-
thology. One possible reason for this discrepancy was the 
difference in time between the last biopsy and liver function 
monitoring. Patients were not routinely subjected to biopsy 180 
days after conversion to FK506 if liver function tests were 
normal. Therefore, pathologic analysis alone may have under-
estimated the response. 
Renal functions were presented in this study only as a 
backdrop to events occurring in the liver grafts. However, it is 
noteworthy that the results achieved were not at the expense 
of renal function. Although renal function temporarily wors-
ened at the time of the drug switch, average creatinine values 
180 days after FK506 conversion were lower than pre-FK506 
levels in patients who had received CsA for less than 300 days. 
A slight increase in serum creatinine was noted in those who 
had received esA for a longer period. Neither change was 
statistically significant. The possibility that longer CsA treat-
ment had led to permanent renal structural damage (7,8) must 
be considered. 
Hepatotoxicity of FK506 could not be clearly evaluated in 
this patient population. It is possible but improbable that 
FK506 could be associated with a cholestatic hepatitis or ter-
minal hepatic vein phlebitis. Neither of the above lesions 
appeared to result from a direct hepatotoxic effect of FK506. 
There was no direct association of these injury patterns with 
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serum FK506 levels or FK506 dosage (data not shown). In 
addition, similar, if not identical, lesions were often present in 
the same patients prior to FK506 introduction and have been 
described in other liver allograft recipients treated with cyclo-
sporine (9) or azathioprine (10). These observations are con-
trary to the temporal eligibility requirement for an adverse drug 
reaction (11). Whether the concomitant reduction in steroids 
will effect these manifestations of rejection will require further 
study. 
Weare hesitant also to ascribe the arterial necrosis seen in 
two failed allografts to drug toxicity since it is commonly seen 
in rejecting liver allografts under different immunosuppression 
or in untreated animals (12, 13). Such questions are best 
addressed in patients in whom the target organ is not an 
allograft (i.e., liver studies in heart or kidney recipients). 
Our data suggest that FK506 is more potent than other 
current agents, although an alternative explanation could be 
offered for our results. Based on in vitro data (4), it could be 
speculated that conversion to a new immunosuppressant after 
the development of rejection affects a clone of lymphocytes 
that was selected because of its resistance to the original agent 
or regimen. Direct comparison, as is now being done in a 
randomized trial should yield answers, as well as quantification 
of side-effects. These comparisons of FK506 with conventional 
immunosuppression in historical control patients already have 
placed FK506 in favorable light (14). 
In summary, a clinicopathologic analysis was carried out on 
96/136 patients who were switched from standard esA to 
FK506 immunosuppression. The majority of the patients whose 
dysfunction was ascribable to acute cellular or the early stages 
of chronic rejection despite conventional therapy responded 
favorably to the conversion, along with reduction or discontin-
uance of steroid therapy and stopping of other adjuvant ther-
apy. Nonrejection causes of graft dysfunction were mostly 
unaffected pathologically by FK506, except for progressive 
hepatitis, which proved to be a poor indication for conversion. 
Transient FK506 nephrotoxicity was observed at the time of 
drug switch and this was severe in some patients, but in the 
whole group there was no significant change in mean serum 
creatinine after 180 days of FK506. The results in the larger 
collection of patients with much longer follow-up are similar to 
those reported in the first clinical trials of FK506 in humans 
(1,2). 
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